IN8bio, Inc. (INAB)

IN8bio, Inc. (INAB) Healthcare & Pipeline Overview

IN8bio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of gamma-delta T cell therapies for oncology. Focused on advancing its pipeline, including lead candidates INB-200 for glioblastoma and solid tumors, and INB-100 for acute leukemia, the company aims to address significant unmet medical needs in cancer treatment.

What Is the Investment Thesis for INAB?

IN8bio, Inc. represents a clinical-stage biotechnology entity focused on advancing gamma-delta T cell therapies for oncology, a field with substantial unmet medical needs. The investment thesis centers on the potential of its pipeline, particularly the lead candidates INB-200 and INB-100, both currently in Phase I clinical trials. INB-200 targets glioblastoma and solid tumors, areas characterized by aggressive disease and limited therapeutic success, while INB-100 addresses acute leukemia patients undergoing stem cell transplantation, offering an allogeneic approach. Successful progression through these early-stage trials, demonstrating favorable safety profiles and preliminary efficacy signals, would serve as significant value inflection points. The company's strategic focus on gamma-delta T cells, which possess unique innate and adaptive immune properties, differentiates its approach within the competitive cell therapy landscape. However, as a clinical-stage company with a market capitalization of $13.71M and no current revenue streams, its valuation is heavily reliant on future clinical data, regulatory approvals, and eventual commercialization success, introducing inherent development risks typical of the biotechnology sector.

Based on FMP financials and quantitative analysis

INAB Key Highlights

• Clinical-Stage Pipeline: IN8bio, Inc. maintains a pipeline of gamma-delta T cell therapies, with lead candidates INB-200 and INB-100 both in Phase I clinical trials for glioblastoma/solid tumors and acute leukemia, respectively.
• Focused Therapeutic Area: The company is exclusively dedicated to oncology, specifically leveraging gamma-delta T cells for cancer treatment, indicating a specialized approach within the broader biotechnology sector.
• Early-Stage Development: With all programs either in Phase I clinical trials or preclinical stages, IN8bio's valuation is primarily driven by future clinical milestones and the potential of its technology.
• Market Capitalization: The company has a market capitalization of $13.71M, reflecting its early-stage status and the significant development hurdles typical of biotechnology firms.
• Lean Operational Structure: IN8bio operates with approximately 18 employees, suggesting a focused and potentially agile research and development organization.

Who Are INAB's Competitors?

INAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INAB's Key Strengths?

• Focused pipeline of gamma-delta T cell therapies addressing high-unmet-need cancers.
• Lead candidates INB-200 and INB-100 in Phase I clinical trials.
• Unique biological properties of gamma-delta T cells (innate tumor recognition, allogeneic potential).
• Dedicated team with specialized expertise in cell therapy and oncology.

What Are INAB's Weaknesses?

• Early-stage clinical development with no commercialized products or revenue.
• Small employee base (18 employees) for extensive R&D efforts.
• High capital requirements typical of biotechnology R&D.
• Reliance on successful clinical trial outcomes for future viability.

What Could Drive INAB Stock Higher?

• Release of initial safety and efficacy data from the ongoing Phase I clinical trial for INB-200 in glioblastoma and solid tumors.
• Presentation of early clinical data or updates from the Phase I clinical trial for INB-100 in acute leukemia patients undergoing hematopoietic stem cell transplantation.
• Progression of preclinical candidates INB-400 and INB-300 towards Investigational New Drug (IND) application submissions, signaling readiness for human trials.
• Potential for new strategic collaborations or licensing agreements with larger pharmaceutical partners to support pipeline development and commercialization efforts.

What Are the Key Risks for INAB?

• Financial-distress signal — its Altman Z-Score of -6.86 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-96.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures, including insufficient efficacy or unacceptable safety profiles, for lead candidates INB-200 and INB-100, which would significantly impact the company's valuation and future prospects.
• Significant capital requirements for continued research and development, potentially necessitating future equity financing that could lead to shareholder dilution.
• Intense competition within the oncology and cell therapy landscape from larger, well-funded pharmaceutical and biotechnology companies with established platforms and commercialized products.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities like the FDA, which are inherent to the drug development process for novel therapies.
• Dependence on intellectual property protection for its gamma-delta T cell technology, with risks related to patent challenges or the inability to secure broad patent coverage.

What Are the Growth Opportunities for INAB?

• Advancement of INB-200 for Glioblastoma and Solid Tumors: The successful progression of INB-200 through Phase I and into later-stage clinical trials represents a significant growth opportunity. Glioblastoma is an aggressive brain cancer with a median survival of only 15-18 months, representing a substantial unmet medical need. The global glioblastoma multiforme treatment market size was valued at approximately $1.1 billion in 2022 and is projected to grow. Demonstrating positive safety and preliminary efficacy data for INB-200 could attract partnerships or significant investment, validating IN8bio's autologous gamma-delta T cell platform and opening pathways for broader solid tumor applications.
• Clinical Development of INB-100 for Acute Leukemia: INB-100, an allogeneic gamma-delta T cell therapy for acute leukemia patients undergoing hematopoietic stem cell transplantation, offers another critical growth pathway. Acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), affects thousands globally each year. The global acute leukemia market is projected to reach over $10 billion by 2030. The allogeneic nature of INB-100 could provide a more accessible and scalable treatment option compared to patient-specific autologous therapies, potentially accelerating its development and market penetration if clinical milestones are met.
• Expansion of Preclinical Pipeline (INB-400 and INB-300): The advancement of INB-400 and INB-300 from preclinical stages into Investigational New Drug (IND) applications and subsequent clinical trials for various solid tumor cancers represents future growth. These programs broaden IN8bio's therapeutic reach and diversify its risk profile beyond its lead candidates. The global solid tumor market is vast, estimated at over $200 billion annually, offering numerous potential indications. Successful preclinical development and IND clearance would validate the company's research capabilities and expand its addressable market in the long term, likely within a 3-5 year timeframe for initial clinical data.
• Strategic Partnerships and Collaborations: As a clinical-stage biotechnology company with a market capitalization of $13.71M, securing strategic partnerships with larger pharmaceutical companies could provide crucial funding, manufacturing expertise, and broader commercialization capabilities. Such collaborations, potentially involving licensing agreements or co-development deals, could significantly accelerate the development and market access of IN8bio's gamma-delta T cell therapies. These partnerships could target specific indications or geographic regions, leveraging the partner's resources to de-risk development and expand market potential, potentially within the next 2-4 years.
• Platform Validation and New Indications: Successful clinical data from INB-200 and INB-100 would validate IN8bio's gamma-delta T cell platform, potentially enabling its application to a wider range of cancer indications. The unique properties of gamma-delta T cells, including their ability to recognize and kill tumor cells without prior sensitization and their potential for off-the-shelf use, could position the company as a leader in this emerging therapeutic area. This validation could lead to the initiation of new programs targeting additional high-need cancers, expanding the company's total addressable market over a 5-10 year horizon as the platform matures.

What Opportunities Does INAB Have?

• Significant market potential in glioblastoma, acute leukemia, and solid tumors.
• Potential for strategic partnerships and collaborations to accelerate development and commercialization.
• Expansion of the gamma-delta T cell platform into new cancer indications.
• Advancements in cell therapy manufacturing and delivery technologies.

What Threats Does INAB Face?

• High risk of clinical trial failures (efficacy or safety).
• Intense competition from larger pharmaceutical and biotechnology companies in oncology.
• Stringent and evolving regulatory landscape for cell therapies.
• Need for significant future funding rounds, potentially leading to dilution.

What Are INAB's Competitive Advantages?

• Proprietary Gamma-Delta T Cell Platform: Focus on a unique subset of T cells with distinct anti-tumor mechanisms, potentially offering advantages over conventional alpha-beta T cell therapies.
• Clinical Trial Data: Accumulation of proprietary clinical data from ongoing Phase I trials (INB-200, INB-100) provides a competitive edge and informs future development.
• Intellectual Property: Development of patents and other intellectual property around their specific cell therapy constructs, genetic modifications, and manufacturing processes.
• Specialized Expertise: A dedicated team of 18 employees focused specifically on gamma-delta T cell biology and oncology, fostering deep expertise in this niche area.

What Does INAB Do?

IN8bio, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative gamma-delta T cell therapies for the treatment of various cancers. Established in 2016, the company initially operated under the name Incysus Therapeutics, Inc., before rebranding to IN8bio, Inc. in August 2020. Headquartered in New York, New York, IN8bio is at the forefront of exploring the therapeutic potential of gamma-delta T cells, a unique subset of T lymphocytes that possess innate tumor-killing capabilities and can bridge innate and adaptive immunity. The company's pipeline features several product candidates targeting different cancer types. Its most advanced program is INB-200, a genetically modified autologous gamma-delta T cell product candidate currently undergoing a Phase I clinical trial. This candidate is being investigated for its efficacy and safety in treating glioblastoma, a highly aggressive form of brain cancer, as well as other solid tumors. Glioblastoma represents a significant challenge in oncology due to its poor prognosis and limited treatment options, making INB-200 a potential therapeutic advancement in this area. Another key product candidate is INB-100, an allogeneic gamma-delta T cell therapy. This candidate is also in a Phase I clinical trial, specifically designed to treat patients with acute leukemia who are undergoing hematopoietic stem cell transplantation. The allogeneic nature of INB-100 suggests a potential for off-the-shelf availability, which could offer advantages in terms of manufacturing and patient accessibility compared to autologous therapies. Beyond these lead candidates, IN8bio is actively developing earlier-stage programs, including INB-400 and INB-300. Both of these candidates are in the preclinical phase, with a focus on addressing various solid tumor cancers. The company's strategic approach involves leveraging the inherent anti-tumor properties of gamma-delta T cells, either through genetic modification or allogeneic platforms, to create novel immunotherapies. With a focused team of 18 employees, IN8bio is committed to advancing its research and clinical programs to bring new treatment options to cancer patients.

What Products and Services Does INAB Offer?

• Discover and develop novel gamma-delta T cell therapies for cancer treatment.
• Conduct clinical trials for lead product candidates like INB-200 and INB-100.
• Focus on genetically modified autologous gamma-delta T cells (INB-200) for glioblastoma and solid tumors.
• Develop allogeneic gamma-delta T cell therapies (INB-100) for acute leukemia patients undergoing stem cell transplantation.
• Advance preclinical programs (INB-400, INB-300) for various solid tumor cancers.
• Engage in research and development to leverage the unique anti-tumor properties of gamma-delta T cells.
• Operate as a clinical-stage biotechnology company, primarily focused on R&D activities.

How Does INAB Make Money?

• Currently, IN8bio operates as a research and development entity, with no commercialized products or revenue streams.
• Future revenue generation is anticipated through the successful development, regulatory approval, and commercialization of its gamma-delta T cell therapy product candidates.
• Potential revenue streams could also include upfront payments, milestone payments, and royalties from licensing agreements or strategic partnerships with larger pharmaceutical companies.
• The company's long-term business model relies on intellectual property protection (patents) for its cell therapy platforms and product candidates.

What Industry Does INAB Operate In?

IN8bio, Inc. operates within the highly innovative and rapidly evolving biotechnology industry, specifically focusing on the oncology sector with its gamma-delta T cell therapies. The broader healthcare sector is experiencing a significant shift towards advanced immunotherapies, with cell therapies, including CAR-T and TCR therapies, gaining prominence in cancer treatment. The global cell therapy market size was valued at approximately $10.1 billion in 2022 and is projected to grow substantially, driven by increasing cancer prevalence and advancements in cellular engineering. IN8bio positions itself within this competitive landscape by concentrating on gamma-delta T cells, a distinct subset of T cells that offer potential advantages such as innate tumor recognition, allogeneic potential, and a favorable safety profile compared to alpha-beta T cells. While the market for cell therapies is dominated by larger pharmaceutical and biotechnology companies with approved CAR-T products, IN8bio's niche focus on gamma-delta T cells aims to carve out a unique space, addressing indications like glioblastoma and acute leukemia where current treatments have limitations. The company's success will depend on its ability to demonstrate superior efficacy and safety in clinical trials, navigating a landscape characterized by high R&D costs and stringent regulatory requirements.

Who Are INAB's Key Customers?

• Ultimately, the primary beneficiaries and indirect "customers" will be cancer patients suffering from conditions like glioblastoma, acute leukemia, and various solid tumors.
• Direct customers, upon commercialization, would include hospitals, oncology clinics, and healthcare systems that administer advanced cell therapies.
• Oncologists, hematologists, and neuro-oncologists would be key prescribers and advocates for IN8bio's therapies.
• Research institutions and academic centers involved in clinical trials are current partners in development.

Company Profile

IN8bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Tai-Wei. INAB has traded publicly since 2021.

How IN8bio, Inc. Is Valued

IN8bio, Inc. carries a market capitalization of $13.71M, placing it in the micro-cap category. Relative to its peer group, INAB's quantitative score of 31/100 is below the peer average of 76/100.

ROE -96%Key Financial Metrics

Return on equity for IN8bio, Inc. stands at -96.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -72.3%, showing how much profit it generates from its asset base. A current ratio of 10.50 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 3/9Financial Health

IN8bio, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.86 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project IN8bio, Inc. revenue of about $47.7M for fiscal 2026, with EPS near $-1.24. The estimate reflects 4 contributing analysts.

Net buyingInsider Activity

Over the past six months, IN8bio, Inc. insiders filed 14 SEC Form 4 transactions — 1 sales and 13 purchases. On net that is roughly 143K shares acquired (about $1.5M) — insiders putting money in tends to read as conviction.

INAB Financials

INAB Latest News

INAB Analyst Consensus

INAB MoonshotScore

INAB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources